Protalix BioTherapeutics shares rise 2.65% after-hours after reporting a 50% increase in revenues for the first half of 2025.

Protalix Biotherapeutics, Inc. rose 2.65% in after-hours trading, following the company's announcement of a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period in 2024. The company also reported its second-quarter 2025 financial results and provided a business and clinical update.